9month28Today, Frost & SullivanFrost & SullivanCo-hosted by Frost & Sullivan, LeadLeo and Huajun Media Group, with the participation of Titanium Media and Roadshow in China.2022The inaugural New Investment Expo and the 16th Frost & Sullivan Global Growth, Innovation and Leadership Summit BioTech Investment Forum successfully concluded.
Today, the biotechnology sector has become a dazzling pearl in the capital market. The opening of the Hong Kong Stock Exchange and the Sci-Tech Innovation Board to unprofitable enterprises has further catalyzed a capital boom. However, due to unfavorable macroeconomic factors in recent years and structural challenges faced by biotechnology companies themselves, the performance of biotechnology companies in the capital market varies. Therefore, how to discover new tracks and seize new opportunities in an environment where crises coexist has become a hot topic among investors and entrepreneurs.
The forum, themed 'New Trends in Biotech Investment and Financing', invited eight heavyweight guests and three Frost & Sullivan healthcare industry experts. It brought together a multitude of biotech companies, investment institutions, and professional service providers to jointly focus on new trends in biotech investment and financing, explore forward-looking investment opportunities in biotechnology, and discuss the successful paths of biotech companies in the capital market. At the same time, Frost & Sullivan's Global2022Biotechnology Growth, Innovation and Leadership Awards (abbreviation:GILAward-winning enterprises.
Dr. Wang Xin, Global Partner at Frost & Sullivan and President of Greater China, Founder and Chairman of LeadLeo, delivered a welcome speech for the conference, which was grandly opened. Dr. Wang Xin stated that over the past decade or so, the development of biotech companies in China has essentially been about 'crossing the river by feeling the stones'. The rapid market explosion started with2018Released by the Hong Kong Stock Exchange18Achapter. and Capital investment is an indispensable and important factor in driving the growth of biotech companies, and it is crucial for promoting research and development and accelerating commercial success in the life sciences industry. He pointed out that in the face of the inevitable cyclical nature of the industry, to find more certain investment opportunities in the biopharmaceutical field, it is necessary to conduct long-term and continuous in-depth research on technological trends, policy changes, and industry dynamics in the biotechnology sector. Frost & Sullivan's Healthcare practice is based in China.60The remaining analyst team has been dedicated to in-depth industry and enterprise research for a long time, enabling seamless integration while helping to meet the supply and demand sides of investment and financing.
Dr. Wang Xin, Global Partner and President of Frost & Sullivan Greater China Region, Founder and Chairman of LeadLeo, delivered a speech at the conference.
Discovering Hidden Dragons in High-Potential Tracks: 2022Announcements of Annual Biotech Growth, Innovation and Leadership Awards
At the meeting, Mr. Wang Chenhui, Managing Partner and Executive Vice President of Frost & Sullivan Greater China Region, Co-founder and President of LeadLeo, delivered speeches on the awards won this year respectively.GILBeijing Zehui Chenxing Biotechnology Co., Ltd. was awarded the 'Global Multi-Potent Stem Cell Drug Leadership Award', and Chongqing Jinshan Medical Robot Co., Ltd. was presented with the 'China MedicalRobotics Innovation Award".
Beijing Zehui Chenxing Biotechnology Co., Ltd.CMODr. Jia Yi takes the stage to receive his award
Ms. Wang Liao, founder of Chongqing Jinshan Medical Robotics Co., Ltd., took the stage to receive her award
Focus on Biotechnology Hotspots:CDMOThe white paper "Industrial Current Situation and Future Development Trends Report" is officially released
Mr. Li Dongyi, Director of Healthcare Consulting at Frost & Sullivan, delivered a grand launch ofCDMO companyIndustrial Current Situation and Future Development Trend Report》, which aims at ChinaCDMOConduct an in-depth analysis of the industry, exploring various aspects such as industry overview, capital enthusiasm, and competitive landscape.CDMOExplore the industry value, investigate the driving force factors and trends behind industry development, and track the iterative context of production technology.
This report focuses onCDMOWhile the overall industry operation is performing well, focus on eachCDMO companyThe current development status of segmented fields, in China and globallyCDMOThe overall industry landscape and key tracks were analyzed for market size, reflecting past ChinaCDMOThe development history of each sub-field, as well as for the futureCDMOForecast the future prospects of market growth space.
We would like to express our special gratitude to Kanglong Chemical Technology, Dongyao Pharmaceutical, and Yaohai Biotechnology for their support of this report.
Kang Long Huacheng Securities' General Supervising Officer Yang (left), Dongyao Pharmaceutical's Financial Director Xiao Ben (middle), and Wang Manchao, Founder Partner, Director and General Manager of Yaohai Biotechnology (right).
Three major professional topics, discussing the development and future of the biotechnology investment and financing market
The first session of the conference was delivered by Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, who shared the theme of2022Review and Prospect of the Biomedical Investment and Financing Market in 2023
Mr. Mao Hua said that the biopharmaceutical capital market has not entered a winter period, and the investment and financing market tends to be 'prudent'.+Rationality: Investors tend to invest earlier, targeting smaller companies with more hardcore technology. This provides certain room for maneuver for investment institutions, and even in the early stages, they still offer high valuations to tech-intensive enterprises.
In addition, Mr. Mao Hua also stated that industrial capital has emerged as a new force, and the professional investment institutions and financing relay mechanism are gradually being improved, promoting the healthy development of the biotechnology industry. Mr. Mao Hua summarized that investment and financing, as well as enterprise operations, complement each other. In the past, products reached clinical trialsIIIn the future, enterprises need to plan pricing, sales strategies after product launch, and at what discount rates they can enter into medical insurance. Now, enterprises need to go a step further by making early plans during financing.
Partner and Managing Director, Greater China, Frost & Sullivan Mr. Mao Hua
Dr. Wang Shu, Deputy General Manager of Yikelei Biotechnology, shared the theme 'Because We Believe Therefore, upon seeing 'A Brief Discussion on Synthetic Biology', Dr. Wang Shu systematically organized the definition, research content, and industry overview of synthetic biology. He pointed out that synthetic biology has opened a new era in scientific research, and its application potential is gradually emerging. The core technology of synthetic biomanufacturing is to construct efficient microbial cell factories. All pathways need to be assembled, balanced, and optimized within this factory to achieve results, thereby converting biomass raw materials into various end products. How to expand the variety of chemicals produced by microbial cells and how to improve cell production efficiency are currently two very critical issues limiting the industrialization of cell factories. Dr. Wang Shu stated that synthetic biology is a field that many countries have attached great importance to in recent years, especially driven by carbon neutrality. The competitiveness of synthetic biology is gradually emerging, and its future development potential cannot be underestimated.
Vice General Manager of Yikelei Biotechnology Dr. Wang Shu
Mr. Zhu Jielun, Chief Financial Officer and Chief Investment Officer of Feipeng Group, delivered a keynote speech titled "How Biotech Companies Efficiently Meet Their Financing Needs." He believes that the essence of the capital market is an amplifier, and participants generally have a herd mentality, leading to phenomena such as following trends and magnifying them. At the same time, he believes that in the vast ocean of the capital market, discovering, grasping, and utilizing cycles is the key to success. Finally, Mr. Zhu Jielun summarized the high-qualityIRThe qualities required include the ability to manage expectations externally, integrate information internally, possess a sincere trait, and also convey real-time market capitalization information within departments.
Chief Financial Officer and Chief Investment Officer of Feipeng Group Mr. Zhu Jielun
Roundtable Discussion: Exploring the New Pattern of Industry Development
A roundtable forum was specially set up at this summit, where leaders and experts from multiple companies shared their industry experiences and insights on hot topics such as how biotech companies choose diverse listing locations.
Mr. Ren Mengqi, Executive General Manager of Investment Banking at CICC, Mr. Geng Ke, Managing Partner at Meimes Law Firm, Mr. Fei Fan, Co-Head of Life Sciences and Healthcare at EY Greater China, Mr. Li Ankang, Chief Financial Officer and Chief Strategy Officer at Tengsheng Bo Pharmaceutical, and Mr. Wang Shuguang, Managing Partner and General Manager at Shanghai Wen Zhou Investment Management Co., Ltd., engaged in an in-depth discussion around 'hot topics such as how biopharmaceutical technology companies choose diverse listing locations'. Mr. Zhu Yi, Executive Director of Frost & Sullivan, served as the moderator for this roundtable.
Mr. Ren Mengqi, Executive General Manager of Investment Banking at CICC, stated that although the capital market has recently entered a low point, it has also given investors time to calm down and identify what truly constitutes a good company.
Mr. Geng Ke, Managing Partner of Meimas Law Firm, mentioned recent bills and cases affecting the capital market of the biotech industry, pointing out that the review of Chinese companies acquiring US companies has become increasingly stringent.
Mr. Fei Fan, Co-Head of Life Sciences and Healthcare at EY Greater China, mentioned that against the backdrop of an overall pessimistic environment, companies need to achieve 'wait, save, and integrate'. First, they should wait for the macro environment to improve, then save cash by keeping it safe and making full use of it, and finally integrate it. Although companies now face issues such as declining valuations when financing, they still need money to operate.
Mr. Li Ankang, Chief Financial Officer and Chief Strategy Officer of Tengsheng Boyao, stated that there are many uncertainties in the current market, and businesses need to adjust their business priorities. In addition, it is necessary to raise the standards for doing business and products, as enterprises are facing a more competitive market and more discerning investors under the current macro environment.
Mr. Wang Shuguang, the managing partner and general manager of Shanghai Wen Zhou Investment Management Co., Ltd., stated that his institution is engaged in earlier-stage investments and has not experienced difficulties in financing or a severe winter-like environment. As an investment institution, it is necessary to prioritize investment research, understand national policy trends, and identify companies whose products truly have clinical advantages.
In addition, as one of the representatives of the partners, Mr. Zhou Yujian, managing partner of Power Health Fund Management, sent his blessings to the conference via video. Mr. Zhou Yujian stated that Power Health Fund is honored to work with Frost & Sullivan to play a role in the global development layout and joint efforts of Chinese biopharmaceutical enterprises.
PowerHealth Fund Management Partnership Mr. Zhou Yujian
The conference successfully concluded amidst warm applause. We would like to express our gratitude to all the distinguished guests and experts for their support of the Frost & Sullivan Biopharmaceutical Technology Investment Forum.
